-
1
-
-
84928062583
-
Immune checkpoint blockade: A common denominator approach to cancer therapy
-
Topalian SL, Drake CG, Pardoll DM. Immune checkpoint blockade: A common denominator approach to cancer therapy. Cancer Cell. 2015;27:450-61.
-
(2015)
Cancer Cell.
, vol.27
, pp. 450-461
-
-
Topalian, S.L.1
Drake, C.G.2
Pardoll, D.M.3
-
2
-
-
84858766182
-
The blockade of immune checkpoints in cancer immunotherapy
-
Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012;12:252-64.
-
(2012)
Nat Rev Cancer.
, vol.12
, pp. 252-264
-
-
Pardoll, D.M.1
-
3
-
-
84255197842
-
Cancer immunotherapy comes of age
-
Mellman I, Coukos G, Dranoff G. Cancer immunotherapy comes of age. Nature. 2011;480:480-9.
-
(2011)
Nature.
, vol.480
, pp. 480-489
-
-
Mellman, I.1
Coukos, G.2
Dranoff, G.3
-
4
-
-
84929481482
-
Nivolumab and ipilimumab versus ipilimumab in untreated melanoma
-
Postow MA, Chesney J, Pavlick AC, et al. Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N Engl J Med. 2015;372:2006-17.
-
(2015)
N Engl J Med.
, vol.372
, pp. 2006-2017
-
-
Postow, M.A.1
Chesney, J.2
Pavlick, A.C.3
-
5
-
-
84924901863
-
Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (checkmate 063): A phase 2, single-arm trial
-
Rizvi NA, Mazieres J, Planchard D, et al. Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (checkmate 063): A phase 2, single-arm trial. Lancet Oncol. 2015;16:257-65.
-
(2015)
Lancet Oncol.
, vol.16
, pp. 257-265
-
-
Rizvi, N.A.1
Mazieres, J.2
Planchard, D.3
-
6
-
-
84862859820
-
Safety, activity, and immune correlates of anti-PD-1 antibody in cancer
-
Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012;366:2443-54.
-
(2012)
N Engl J Med.
, vol.366
, pp. 2443-2454
-
-
Topalian, S.L.1
Hodi, F.S.2
Brahmer, J.R.3
-
7
-
-
84864052441
-
Management of immune-related adverse events and kinetics of response with ipilimumab
-
Weber JS, Kahler KC, Hauschild A. Management of immune-related adverse events and kinetics of response with ipilimumab. J Clin Oncol. 2012;30:2691-7.
-
(2012)
J Clin Oncol.
, vol.30
, pp. 2691-2697
-
-
Weber, J.S.1
Kahler, K.C.2
Hauschild, A.3
-
8
-
-
84953309212
-
Immune-related adverse events with immune checkpoint blockade: A comprehensive review
-
Michot JM, Bigenwald C, Champiat S, et al. Immune-related adverse events with immune checkpoint blockade: A comprehensive review. Eur J Cancer. 2016;54:139-48.
-
(2016)
Eur J Cancer.
, vol.54
, pp. 139-148
-
-
Michot, J.M.1
Bigenwald, C.2
Champiat, S.3
-
9
-
-
84969535050
-
Managing adverse events with immune checkpoint agents
-
Dadu R, Zobniw C, Diab A. Managing adverse events with immune checkpoint agents. Cancer J. 2016;22:121-9.
-
(2016)
Cancer J.
, vol.22
, pp. 121-129
-
-
Dadu, R.1
Zobniw, C.2
Diab, A.3
-
10
-
-
33744792341
-
Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4
-
Beck KE, Blansfield JA, Tran KQ, et al. Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4. J Clin Oncol. 2006;24:2283-2289.
-
(2006)
J Clin Oncol.
, vol.24
, pp. 2283-2289
-
-
Beck, K.E.1
Blansfield, J.A.2
Tran, K.Q.3
-
11
-
-
84975728236
-
Management of toxicities of immune checkpoint inhibitors
-
Spain L, Diem S, Larkin J. Management of toxicities of immune checkpoint inhibitors. Cancer Treat Rev. 2016;44:51-60.
-
(2016)
Cancer Treat Rev.
, vol.44
, pp. 51-60
-
-
Spain, L.1
Diem, S.2
Larkin, J.3
-
12
-
-
85012893091
-
Vedolizumab treatment for immune checkpoint inhibitor-induced enterocolitis
-
Bergqvist V, Hertervig E, Gedeon P, et al. Vedolizumab treatment for immune checkpoint inhibitor-induced enterocolitis. Cancer Immunol Immunother. 2017;66:581-92.
-
(2017)
Cancer Immunol Immunother.
, vol.66
, pp. 581-592
-
-
Bergqvist, V.1
Hertervig, E.2
Gedeon, P.3
-
13
-
-
85034749402
-
Managing toxicities associated with immune checkpoint inhibitors: Consensus recommendations from the society for immunotherapy of cancer (SITC) toxicity management working group
-
Society for Immunotherapy of Cancer Toxicity Management Working Group
-
Puzanov I, Diab A, Abdallah K, et al. ; Society for Immunotherapy of Cancer Toxicity Management Working Group. Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the society for immunotherapy of cancer (SITC) toxicity management working group. J Immunother Cancer. 2017;5:95.
-
(2017)
J Immunother Cancer.
, vol.5
, pp. 95
-
-
Puzanov, I.1
Diab, A.2
Abdallah, K.3
-
14
-
-
85015726665
-
Colonic ulcerations may predict steroid-refractory course in patients with ipilimumab-mediated enterocolitis
-
Jain A, Lipson EJ, Sharfman WH, et al. Colonic ulcerations may predict steroid-refractory course in patients with ipilimumab-mediated enterocolitis. World J Gastroenterol. 2017;23:2023-8.
-
(2017)
World J Gastroenterol.
, vol.23
, pp. 2023-2028
-
-
Jain, A.1
Lipson, E.J.2
Sharfman, W.H.3
-
15
-
-
85015255948
-
Histopathologic features of colitis due to immunotherapy with anti-PD-1 antibodies
-
Chen JH, Pezhouh MK, Lauwers GY, et al. Histopathologic features of colitis due to immunotherapy with anti-PD-1 antibodies. Am J Surg Pathol. 2017;41:643-54.
-
(2017)
Am J Surg Pathol.
, vol.41
, pp. 643-654
-
-
Chen, J.H.1
Pezhouh, M.K.2
Lauwers, G.Y.3
-
16
-
-
84963860995
-
Clinical, endoscopic, and histologic characteristics of ipilimumab-associated colitis
-
Verschuren EC, van den Eertwegh AJ, Wonders J, et al. Clinical, endoscopic, and histologic characteristics of ipilimumab-associated colitis. Clin Gastroenterol Hepatol. 2016;14:836-42.
-
(2016)
Clin Gastroenterol Hepatol.
, vol.14
, pp. 836-842
-
-
Verschuren, E.C.1
Van Den Eertwegh, A.J.2
Wonders, J.3
-
17
-
-
70350244517
-
Cytotoxic T-lymphocyte-associated antigen 4 antibody-induced colitis and its management with infliximab
-
Johnston RL, Lutzky J, Chodhry A, et al. Cytotoxic T-lymphocyte-associated antigen 4 antibody-induced colitis and its management with infliximab. Dig Dis Sci. 2009;54:2538-40.
-
(2009)
Dig Dis Sci.
, vol.54
, pp. 2538-2540
-
-
Johnston, R.L.1
Lutzky, J.2
Chodhry, A.3
-
18
-
-
84940746759
-
Immune related adverse events associated with anti-CTLA-4 antibodies: Systematic review and meta-analysis
-
Bertrand A, Kostine M, Barnetche T, et al. Immune related adverse events associated with anti-CTLA-4 antibodies: systematic review and meta-analysis. BMC Med. 2015;13:211.
-
(2015)
BMC Med.
, vol.13
, pp. 211
-
-
Bertrand, A.1
Kostine, M.2
Barnetche, T.3
-
19
-
-
84899710302
-
Early administration of infliximab for severe ipilimumab-related diarrhea in a critically ill patient
-
Merrill SP, Reynolds P, Kalra A, et al. Early administration of infliximab for severe ipilimumab-related diarrhea in a critically ill patient. Ann Pharmacother. 2014;48:806-10.
-
(2014)
Ann Pharmacother.
, vol.48
, pp. 806-810
-
-
Merrill, S.P.1
Reynolds, P.2
Kalra, A.3
|